{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:50:01Z","timestamp":1792043401929,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Several anticancer drugs can cause chemotherapy-induced peripheral neurotoxicity (CIPN) in approximately 70% of patients; of these, 30% continue to have chronic symptoms hampering quality of life. As more people live with and beyond cancer therapy, it is becoming increasingly important for clinicians to assess those at higher risk of CIPN and provide care for managing CIPN severity. Biomarkers could be appropriate in this regard. However, an initial step towards biomarker-informed care is to advance scientific knowledge regarding the potential of current biomarkers such as neurofilament light chain (NfL). Here, outcomes of a CIPN biomarker workshop and discussions among clinical and scientific experts held during the MASCC 2024 annual conference are reported. The aims of this work are to (1) identify knowledge gaps regarding the potential for serum NfL (sNfL) as a predictive CIPN biomarker, (2) provide guidance for future biomarker research, and (3) explore whether sNfL is ready for use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consensus of the experts was gained using a Normative Group Technique. A two-stage iterative approach was used: Stage 1 involved a literature review and an in-person workshop; Stage 2 involved a virtual zoom event to confirm understanding and priorities following the workshop.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven studies identified that increases in serum NfL after receiving 2\u20133 chemotherapy doses are associated with CIPN severity post treatment. Despite preliminary evidence suggesting positive correlations among sNfL and CIPN objective and subjective measures, wide variation in sNfL levels, the prescribed neurotoxic chemotherapy agent, dose and schedule, and symptom assessment time points make it difficult to use sNfL as a predictor of CIPN severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While there is potential for sNfL to be a useful biomarker, larger scale research exploring the predictive value is needed before sNfL can be used to inform clinical decision-making. Identifying links with validated clinical assessments could be utilized to enhance biomarker accuracy and to address the multiple pathological mechanisms of neurotoxicity that occur from the differing chemotherapies. Moreover, workshop participants identified significant barriers to biomarker implementation (e.g. costs, long processing time, and unknown cut off points).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10690-2","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:50:24Z","timestamp":1778122224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice\u2014a narrative review"],"prefix":"10.1007","volume":"34","author":[{"given":"Paola","family":"Alberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Faithfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balayssac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Tanay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Jabaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Worthen-Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MASCC Neurological complications study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"12","key":"10690_CR1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461\u20132470","journal-title":"Pain"},{"key":"10690_CR2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174","journal-title":"Front Mol Neurosci"},{"key":"10690_CR3","doi-asserted-by":"crossref","unstructured":"McCrary JM et al (2019) Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments. J Natl Compr Canc Netw 17(8):949\u2013955","DOI":"10.6004\/jnccn.2019.7290"},{"issue":"5","key":"10690_CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-020-00903-0","volume":"22","author":"CS Tofthagen","year":"2020","unstructured":"Tofthagen CS, Cheville AL, Loprinzi CL (2020) The physical consequences of chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 22(5):50","journal-title":"Curr Oncol Rep"},{"key":"10690_CR5","doi-asserted-by":"crossref","unstructured":"Cavaletti G et al (2019)\u00a0Patients\u2019 and physicians\u2019 interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(1):111\u2013119","DOI":"10.1111\/jns.12332"},{"issue":"2","key":"10690_CR6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11764-017-0662-8","volume":"12","author":"C Miaskowski","year":"2018","unstructured":"Miaskowski C et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors\u2019 symptom burden and quality of life. J Cancer Surviv 12(2):234\u2013245","journal-title":"J Cancer Surviv"},{"issue":"5","key":"10690_CR7","first-page":"4007","volume":"30","author":"M Wang","year":"2022","unstructured":"Wang M, Molassiotis A (2022) Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data. Support Care Cancer 30(5):4007\u20134017","journal-title":"Support Care Cancer"},{"issue":"28","key":"10690_CR8","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"key":"10690_CR9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102241","volume":"99","author":"DL Hertz","year":"2021","unstructured":"Hertz DL et al (2021) Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev 99:102241","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 2","key":"10690_CR10","first-page":"S6","volume":"24","author":"G Cavaletti","year":"2019","unstructured":"Cavaletti G et al (2019) Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Peripher Nerv Syst 24(Suppl 2):S6\u2013S12","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"10690_CR11","first-page":"3729","volume":"27","author":"A Chan","year":"2019","unstructured":"Chan A et al (2019) Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer 27(10):3729\u20133737","journal-title":"Support Care Cancer"},{"issue":"6","key":"10690_CR12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/djz011","volume":"111","author":"SG Dorsey","year":"2019","unstructured":"Dorsey SG et al (2019) The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. JNCI J Natl Cancer Inst 111(6):531\u2013537","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"10690_CR13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12916-023-03075-3","volume":"21","author":"KV Savva","year":"2023","unstructured":"Savva KV et al (2023) The biomarker toolkit - an evidence-based guideline to predict cancer biomarker success and guide development. BMC Med 21(1):383","journal-title":"BMC Med"},{"key":"10690_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328323","author":"SB Park","year":"2023","unstructured":"Park SB et al (2023) Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2021-328323","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10690_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135739","volume":"749","author":"C Meregalli","year":"2021","unstructured":"Meregalli C et al (2021) Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: from preclinical models to clinical practice. Neurosci Lett 749:135739","journal-title":"Neurosci Lett"},{"issue":"7","key":"10690_CR16","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11064-023-03873-4","volume":"48","author":"VK Sharma","year":"2023","unstructured":"Sharma VK et al (2023) Biomarkers: role and scope in neurological disorders. Neurochem Res 48(7):2029\u20132058","journal-title":"Neurochem Res"},{"key":"10690_CR17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2340\/1651-226X.2024.39895","volume":"63","author":"J Adra","year":"2024","unstructured":"Adra J et al (2024) Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy. Acta Oncol 63:636\u2013641","journal-title":"Acta Oncol"},{"issue":"12","key":"10690_CR18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/17425255.2021.1842873","volume":"16","author":"P Alberti","year":"2020","unstructured":"Alberti P (2020) A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy. Expert Opin Drug Metab Toxicol 16(12):1147\u20131158","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10690_CR19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2024.08.001","volume":"45","author":"NE Andersen","year":"2024","unstructured":"Andersen NE et al (2024) Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy. Trends Pharmacol Sci 45(10):872\u2013879","journal-title":"Trends Pharmacol Sci"},{"key":"10690_CR20","volume":"3","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL et al (2022) Biomarkers of chemotherapy-induced peripheral neuropathy: current status and future directions. Front Pain Res (Lausanne) 3:864910","journal-title":"Front Pain Res (Lausanne)"},{"issue":"7","key":"10690_CR21","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00204-020-02755-w","volume":"94","author":"C Meregalli","year":"2020","unstructured":"Meregalli C et al (2020) Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol 94(7):2517\u20132522","journal-title":"Arch Toxicol"},{"issue":"2","key":"10690_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3928\/01484834-20200122-02","volume":"59","author":"S Cooper","year":"2020","unstructured":"Cooper S et al (2020) The nominal group technique: generating consensus in nursing research. J Nurs Educ 59(2):65\u201367","journal-title":"J Nurs Educ"},{"issue":"1","key":"10690_CR23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/0142159X.2017.1245856","volume":"39","author":"S Humphrey-Murto","year":"2017","unstructured":"Humphrey-Murto S et al (2017) Using consensus group methods such as Delphi and nominal group in medical education research. Med Teach 39(1):14\u201319","journal-title":"Med Teach"},{"issue":"1","key":"10690_CR24","volume":"103","author":"M Aparicio Rodrigo","year":"2025","unstructured":"Aparicio Rodrigo M et al (2025) How to develop and evaluate consensus documents: methods and checklists. An Pediatr (Engl Ed) 103(1):503890","journal-title":"An Pediatr (Engl Ed)"},{"issue":"10","key":"10690_CR25","volume":"31","author":"DL Hertz","year":"2023","unstructured":"Hertz DL, Lustberg MB, Sonis S (2023) Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Support Care Cancer 31(10):601","journal-title":"Support Care Cancer"},{"issue":"2","key":"10690_CR26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.soncn.2012.03.008","volume":"28","author":"C Miaskowski","year":"2012","unstructured":"Miaskowski C, Aouizerat BE (2012) Biomarkers: symptoms, survivorship, and quality of life. Semin Oncol Nurs 28(2):129\u2013138","journal-title":"Semin Oncol Nurs"},{"key":"10690_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174216","author":"G Cavaletti","year":"2023","unstructured":"Cavaletti G et al (2023) Studies to assess the utility of serum neurofilament light chain as a biomarker in chemotherapy-induced peripheral neuropathy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15174216","journal-title":"Cancers (Basel)"},{"key":"10690_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154395","author":"P Huehnchen","year":"2022","unstructured":"Huehnchen P et al (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.154395","journal-title":"JCI Insight"},{"key":"10690_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12493","author":"S Karteri","year":"2022","unstructured":"Karteri S et al (2022) Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst. https:\/\/doi.org\/10.1111\/jns.12493","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10690_CR30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","volume":"270","author":"R Velasco","year":"2023","unstructured":"Velasco R et al (2023) Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. J Neurol 270(1):531\u2013537","journal-title":"J Neurol"},{"issue":"9","key":"10690_CR31","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16369","volume":"31","author":"R Velasco","year":"2024","unstructured":"Velasco R et al (2024) Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug. Eur J Neurol 31(9):e16369","journal-title":"Eur J Neurol"},{"issue":"1","key":"10690_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18716-5","volume":"12","author":"BL Burgess","year":"2022","unstructured":"Burgess BL, Cho E, Honigberg L (2022) Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 12(1):15593","journal-title":"Sci Rep"},{"issue":"1","key":"10690_CR33","volume":"10","author":"SH Kim","year":"2020","unstructured":"Kim SH et al (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10(1):7995","journal-title":"Sci Rep"},{"key":"10690_CR34","volume":"12","author":"SH Kim","year":"2022","unstructured":"Kim SH et al (2022) Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. Front Oncol 12:942960","journal-title":"Front Oncol"},{"issue":"7","key":"10690_CR35","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","volume":"164","author":"C Mortensen","year":"2023","unstructured":"Mortensen C et al (2023) Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain 164(7):1502\u20131511","journal-title":"Pain"},{"issue":"6","key":"10690_CR36","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","volume":"270","author":"N Cebulla","year":"2023","unstructured":"Cebulla N et al (2023) Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment. J Neurol 270(6):2997\u20133007","journal-title":"J Neurol"},{"issue":"6","key":"10690_CR37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17425255.2019.1622679","volume":"15","author":"P Alberti","year":"2019","unstructured":"Alberti P (2019) Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol 15(6):487\u2013497","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10690_CR38","first-page":"2553","volume":"28","author":"JS Gewandter","year":"2020","unstructured":"Gewandter JS et al (2020) Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer 28(6):2553\u20132562","journal-title":"Support Care Cancer"},{"key":"10690_CR39","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1571605","volume":"16","author":"D Centonze","year":"2025","unstructured":"Centonze D et al (2025) Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice. Front Neurol 16:1571605","journal-title":"Front Neurol"},{"issue":"5","key":"10690_CR40","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70201","volume":"21","author":"J Rodda","year":"2025","unstructured":"Rodda J et al (2025) Global multi-specialty clinician perspectives on the implementation of Alzheimer\u2019s disease blood biomarkers. Alzheimers Dement 21(5):e70201","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10690_CR41","doi-asserted-by":"crossref","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S et al (2020) Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 10(1):20350","journal-title":"Sci Rep"},{"issue":"12","key":"10690_CR42","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/acn3.51903","volume":"10","author":"G Disanto","year":"2023","unstructured":"Disanto G et al (2023) Longitudinal serum neurofilament light kinetics in post-anoxic encephalopathy. Ann Clin Transl Neurol 10(12):2407\u20132412","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10690_CR43","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf468","volume":"7","author":"CA Leckey","year":"2025","unstructured":"Leckey CA et al (2025) Stable isotope labelling kinetics of neurofilament light. Brain Commun 7(6):fcaf468","journal-title":"Brain Commun"},{"issue":"16_suppl","key":"10690_CR44","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1200\/JCO.2024.42.16_suppl.12005","volume":"42","author":"MS Trivedi","year":"2024","unstructured":"Trivedi MS et al (2024) Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714. J Clin Oncol 42(16_suppl):12005\u201312005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10690_CR45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","volume":"16","author":"B Frigeni","year":"2011","unstructured":"Frigeni B et al (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16(3):228\u2013236","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10690_CR46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/OP.24.00089","volume":"21","author":"MB Heneghan","year":"2025","unstructured":"Heneghan MB et al (2025) Protocol-stipulated dose modification to manage chemotherapy-induced peripheral neuropathy in children, adolescents, and young adults with high-risk Hodgkin lymphoma. JCO Oncol Pract 21(4):526\u2013534","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10690_CR47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895\u2013903","journal-title":"Br J Haematol"},{"issue":"13","key":"10690_CR48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u20131367","journal-title":"JAMA"},{"key":"10690_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2354","author":"F Streckmann","year":"2024","unstructured":"Streckmann F et al (2024) Preventive effect of neuromuscular training on chemotherapy-induced neuropathy: a randomized clinical trial. JAMA Intern Med. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2354","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10690_CR50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","volume":"25","author":"P Alberti","year":"2014","unstructured":"Alberti P et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257\u2013264","journal-title":"Ann Oncol"},{"issue":"3","key":"10690_CR51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","volume":"46","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479\u201394","journal-title":"Eur J Cancer"},{"issue":"7","key":"10690_CR52","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","volume":"97","author":"P Alberti","year":"2021","unstructured":"Alberti P et al (2021) Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity. Neurology 97(7):e660\u2013e672","journal-title":"Neurology"},{"issue":"7","key":"10690_CR53","volume":"9","author":"CS Chen","year":"2021","unstructured":"Chen CS et al (2021) Chemotherapy-induced peripheral neuropathy detection via a smartphone app: cross-sectional pilot study. JMIR Mhealth Uhealth 9(7):e27502","journal-title":"JMIR Mhealth Uhealth"},{"key":"10690_CR54","doi-asserted-by":"crossref","first-page":"117727192513640","DOI":"10.1177\/11772719251364018","volume":"20","author":"E La Civita","year":"2025","unstructured":"La Civita E et al (2025) Advancing clinical use of neurofilament light chain: translational insights from research to routine practice. Biomark Insights 20:11772719251364018","journal-title":"Biomark Insights"},{"issue":"7","key":"10690_CR55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1515\/cclm-2023-0036","volume":"61","author":"B Arslan","year":"2023","unstructured":"Arslan B, Zetterberg H (2023) Neurofilament light chain as neuronal injury marker - what is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med 61(7):1140\u20131149","journal-title":"Clin Chem Lab Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10690-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:27:44Z","timestamp":1781058464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10690"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10690-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a consensus document developed with permission of the workshop participants with consent for publication prior to attending and therefore ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}